Oncimmune Holdings PLC’s (LON:ONC) chief executive Adam Hill said a deal to sell its cancer detection product to a Spanish private healthcare group “highlights the growing momentum behind our business”.
Local distributor Sabartech has inked an agreement with Vithas Group, which operates 48 hospitals and medical centres.
Not only will Vithas buy EarlyCDT lung cancer screening tests, which detect the early stages of the killer diseases, the company’s laboratory will also promote the test throughout Spain.
As Oncimmune pointed out, this is the latest in a series of commercial tie-ups for the lung cancer product in Europe and North America.
"Today's announcement further demonstrates the success of our partnership with Sabartech for the distribution of EarlyCDT Lung across the Iberian Peninsula,” said CEO Hill.
“The news highlights the growing momentum behind our business and further validates our strategy of creating value through partnering to unlock the potential of the EarlyCDT portfolio."
Every year in Spain around 27,000 new cases of lung cancer are diagnosed and 23,000 deaths occur from the disease, making it the largest cause of cancer-related deaths in Spain.